barrett's%20esophagus
BARRETT'S ESOPHAGUS
Barrett's esophagus is defined as the endoscopic finding in the distal esophagus of proximal-appearing columnar-lined esophagus of at least 1-cm length that is confirmed by histology.
It is considered a premalignant metaplastic condition that usually involves the distal esophagus.
It is postulated that exposure of the esophageal epithelium to acid damages the lining resulting in chronic esophagitis and its healing involves metaplastic process.

Barrett's%20esophagus Diagnosis

Screening

Recommendations Regarding Endoscopy in Chronic Gastroesophageal Reflux Disease (GERD) Patients 

  • The main reason to evaluate patients with chronic GERD symptoms is to identify Barrett’s esophagus
    • Patients with chronic GERD are the most at risk to develop Barrett’s esophagus and should undergo upper endoscopy
    • Endoscopy to screen for Barrett’s esophagus is recommended in patients with >5 years of GERD symptoms
    • Routine screening of GERD patients may not be appropriate in the Asian population because of the low prevalence of Barrett’s metaplasia in Asia
  • Patients with alarm symptoms or high risk should be immediately referred for endoscopy to screen for malignancy or Barrett’s esophagus
    • Alarm symptoms: Dysphagia, odynophagia, bleeding, weight loss
  • Those who have had GERD symptoms of >3x/week for >20 years have 40-fold increased risk of developing adenocarcinoma
  • Many patients who develop Barrett’s esophagus are asymptomatic
    • 40% of patients with esophageal adenocarcinoma have no history of GERD
  • Decision to screen should be individualized

Physical Examination

  • Clinicians must examine the patient and look for any sign of extraesophageal disease, complications of advanced disease or any underlying disease that may manifest as GERD

Evaluation

Endoscopy

  • Each upper endoscopy should record the squamocolumnar junction, the gastroesophageal junction (GEJ), presence of a hiatal hernia and the location of the diaphragmatic hiatus in patients suspected of Barrett’s esophagus
    • The Asia-Pacific consensus defines the GEJ as the proximal limits of gastric folds
  • Use Prague criteria in documenting extent of suspected Barrett’s esophagus on endoscopy
  • Consider endoscopic screening in patients with or without history of reflux symptoms and with a family history of >2 first-degree relatives with Barrett’s esophagus or esophageal adenocarcinoma
  • If initial endoscopy is negative, it is not recommended to repeat it; however, in patients with suspected Barrett’s esophagus and negative histology, endoscopy may be repeated in 1-2 years
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.